nasal polyps – Asian Pacific Journal of Allergy and Immunology

HOME
ABOUT
EDITORS
SUBMISSION
- Online Submission
- Author Instructions
ISSUE
PERMISSIONS
CONTACT
ADVERTISE

nasal polyps

January 4, 2022

Nivolumab-induced diffuse type 2 rhinosinusitis: A case report

Nivolumab, an immune checkpoint inhibitor is used to treat advanced metastatic malignancies. Data showed that nivolumab can cause exacerbated response of T-Helper 2 cells and lead to airway inflammation.

chronic rhinosinusitis, Immune check point inhibitor, Immune-related adverse event, nasal polyps, Nivolumab, Programed cell death-ligand

January 4, 2022

TGF-β1 induces epithelial-to-mesenchymal transition in chronic rhinosinusitis with nasal polyps through microRNA-182

Epithelial-to-mesenchymal transition (EMT) in nasal epithelial cells is involved in tissue remodeling of chronic rhinosinusitis with nasal polyps (CRSwNP). Our study investigated the molecular mechanisms that microRNA-182 (miR‑182) regulated EMT in eosinophilic (Eos) and non-eosinophilic (non-Eos) CRSwNP.

Eosinophilic/non-Eosinophilic chronic rhinosinusitis, Epithelial-mesenchymal transition, MicroRNA-182, nasal polyps, Transforming growth factor (TGF)-β1

Key words

allergen Allergic rhinitis Allergy Anaphylaxis Asthma atopic dermatitis child Children Chlorhexidine chronic rhinosinusitis chronic spontaneous urticaria Chronic Urticaria COVID-19 cytokine depression diagnosis drug allergy Drug hypersensitivity efficacy Epidemiology food allergy Food hypersensitivity house dust mite IgE Immunotherapy obstructive sleep apnea Omalizumab prevalence primary immunodeficiency Quality of life Questionnaire Reliability risk factor risk factors safety SARS-CoV-2 Sensitization Severe asthma Skin prick test Specific IgE Thai treatment urticaria vaccine Vitamin D

Support Contact

Managing Editor
Ms. Patrawadee Pitakpolrat
E-mail: managingeditor@apjai-journal.org

Production Editor
Ms. Chanita Jangsawang
E-mail: chanita.j@apjai-journal.org